April 16 (Reuters) - Mayne Pharma Group Ltd MYX.AX :* FDA APPROVAL OF NOVEL ORAL CONTRACEPTIVE NEXTSTELLIS* US FDA APPROVED NEW DRUG APPLICATION FOR NEW ORAL CONTRACEPTIVE...
Feb 24 (Reuters) - Mayne Pharma Group Ltd MYX.AX :* HY UNDERLYING EBITDA $39.9M, DOWN 16%* HY REPORTED REVENUE $208.8 MILLION VERSUS $227.2 MILLION
EU attempting to revive Iran nuclear deal with market staying pessimistic Crude prices could rebound from oversold conditions but stay off 2022 highsBoth Iran, US likely looking...
Mayne Pharma Group Limited is an Australia-based specialty pharmaceutical company focused on commercializing generic pharmaceuticals. The Company operates through four segments: Metrics Contract Services (MCS), International, Branded Products Division (BPD) and Portfolio Products Division (PPD). The MCS segment is engaged in providing contract pharmaceutical development, manufacturing and analytical services to third-party customers, principally in the United States. The PPD segment distributes established products (branded and generic) in the United States on a portfolio basis. The BPD segment distributes medically differentiated specialty products in United States. Its International segment manufactures and sells branded and generic pharmaceutical product globally and the provision of contract development and manufacturing services to third party customers. Its products include Doxycycline Capsules, Oxycodone IR Tablets, Erythromycin Capsules and others.